China Healthcare: Macro Themes
This Insight summarizes the takeaways from a recent China healthcare industry conference. There is much talk of pressures on the industry, but...
474 Views
Eddingpharm: First Impressions
Eddingpharm plans to list on the HKEX. This Insight analyzes the company's products and pipeline. The main question is whether enthusiasm for the...
384 Views
TOT Biopharm (东曜药业) IPO: An Unimpressive Pipeline
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing on the Hong Kong...
854 Views
SillaJen - Pipeline Review & Valuation Study
I surely understand SillaJen, Inc. (0908477D KS) is a very speculative stock to invest right now. It has virtually no revenue. We still have to...
354 Views
Energy Medicine. Personal Experience. Impact. Growth in Asia. Ideas
This is an invest-able idea at the private level with long term benefits. Both for the body, and for other ideas as well.Ever since I turned over...
3.8k Views